Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANPA | Rich Sparkle | $16.31 | -$10.24 | -38.57% | 34K | $331.9M | $2.80$54.75 |
| IMPP | Imperial Petroleum | $4.69 | -$1.31 | -21.83% | 3.6M | $209.1M | $2.12$6.57 |
| SGBX | Safe & Green | $3.26 | -$0.64 | -16.41% | 2M | $22.2M | $1.81$122.88 |
| LEDS | SemiLEDs | $2.02 | -$0.39 | -16.04% | 91K | $19.8M | $1.20$3.37 |
| AGCC | Agencia Comercial Spirits | $6.10 | -$1.07 | -14.92% | 100.8K | $244.6M | $3.66$8.25 |
| LINK | Interlink Electronics | $3.62 | -$0.53 | -12.77% | 120.6K | $65.4M | $2.94$10.10 |
| BUUU | Buuu Group | $7.05 | -$0.97 | -12.10% | 3.6K | $133.7M | $3.67$9.50 |
| AEHL | Antelope Enterprise | $3.09 | -$0.38 | -10.95% | 819K | $11.9M | $1.13$11.53 |
| SONN | Sonnet BioTherapeutics | $3.72 | -$0.44 | -10.47% | 411.8K | $29.4M | $1.08$19.30 |
| IONZ | Tidal Trust II - Defiance Daily Target 2x Short Ionq ETF | $4.13 | -$0.46 | -10.02% | 10.5M | - | $2.08$22.95 |
Related Articles
Featured Article
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Alex Carchidi|Jun 12, 2023
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
Is Arrowhead Pharmaceuticals a Buy Now?
Cory Renauer|Apr 16, 2023
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
George Budwell, PhD|Apr 4, 2023
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
James Halley|Feb 4, 2023
All three healthcare stocks are showing solid long-term potential.
3 Biotech Stocks That Could Go Parabolic in 2022
George Budwell, PhD|Jan 17, 2022
Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Viking Therapeutics could be big winners this year.
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
Cory Renauer|Nov 23, 2021
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Arrowhead Pharmaceuticals: Buy the Dip?
Zhiyuan Sun|Jul 19, 2021
This biotech underdog offers more than meets the eye.
2 Monster Young Biotech Stocks to Add to Your Watchlist
Alex Carchidi|Oct 31, 2020
These biotechs are fueling up for massive market launches.
3 Great Stocks Under $10
Will Healy|Sep 27, 2020
These stocks hold tremendous potential despite a low price.
Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?
Zhiyuan Sun|Jun 2, 2020
Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?
